ABVX Share Price Performance
€104.80
99.44 (1,855.22%)
Price €104.80
Share Pricen/a
ABIVAX Société Anonyme Stock Price
- 1 Narratives written by author
- 0 Comments on narratives written by author
- 18 Fair Values set on narratives written by author
ABVX Community Narratives
There are no narratives available yet.
There are no community narratives available.
Trending Discussion
Recently Updated Narratives
No recently updated narratives available.
Snowflake Analysis
ABIVAX Société Anonyme Key Details
Last Reported Earnings
Dec 31, 2025
Next Reporting Earnings
May 25, 2026
- -4.24
- 100.00%
- -7,354.53%
- 6.6%
About ABVX
- Founded
- 2013
- Employees
- 69
- CEO
- WebsiteView website
ABIVAX Société Anonyme, a clinical-stage biotechnology company, develops therapeutics that harness the body’s natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Its lead drug candidate includes obefazimod, which is in Phase 3 clinical development for the treatment of moderately to severely active UC, as well as Phase 2b clinical trials for Crohn’s disease. The company was incorporated in 2013 and is headquartered in Paris, France.
